IsoPlexis raises $125M in IPO
IsoPlexis completed an initial public offering (IPO) on October 12, closing with $125 million on the sale of approximately 8.3 million shares at $15 per share. Read More
MilliporeSigma doubles viral vector production with new facility
MilliporeSigma has opened a second contract development manufacturing facility in California to focus on viral vector technologies for cell and gene therapy. Read More
AGTC CEO to present at Cell & Gene Meeting on the Mesa
Biotechnology firm Applied Genetic Technologies (AGTC) President and CEO Sue Washer will present at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, on October 13 at 11:15 a.m. PT. Read More
Mission Bio debuts new capabilities for cell, gene therapy
Mission Bio has unveiled its Tapestri Cell & Gene Therapy Solutions, a new addition to its Tapesti platform that can provide analytical characterization of genotype with phenotype simultaneously. Read More
Aceto purchases A&C Bio Buffer
Aceto has acquired A&C Bio Buffer, a good manufacturing practices manufacturer of custom buffer and chemical blend products used in biopharmaceutical drug manufacturing. Read More
Tenaya Therapeutics CEO to present at Cell & Gene Meeting
Faraz Ali, CEO of biotechnology firm Tenaya Therapeutics, will present on October 13 at 3:15 p.m. PT as part of a panel discussion at the Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
GenSight Biologics to highlight gene therapies at Cell & Gene Meeting
French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Century, Outpace partner on CAR engineering
Century Therapeutics and Outpace Bio have entered into a research collaboration on CAR engineering. Read More
Thermo Fisher unveils new NK cell culture medium
Thermo Fisher Scientific has introduced Gibco Cell Therapy Systems NK-Xpander Medium, a new cell culture medium that supports the large-scale growth and culture of functional natural killer (NK) cells for cell and gene therapies. Read More
Learning from older drug modalities accelerates viral process development
Andrew Tustian, EngD, director of viral process development at Regeneron Pharmaceuticals, spoke with about accelerating process development for adeno-associated viruses by modifying strategies from older modalities. Read More
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter